Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with ...